Literature DB >> 2473309

Pressor effects of endothelin-1 and some analogs in the perfused superior mesenteric arterial bed of the rat.

C R Hiley1, S A Douglas, M D Randall.   

Abstract

Human/porcine endothelin-1 (ET-1) dose-dependently increased perfusion pressure in both Krebs-Henseleit and blood-perfused superior mesenteric arterial bed preparations of the rat. In vitro, it was a partial agonist relative to two analogs, [Ala1,15]- and [Ala3,11]-ET-1, and the maximum response was increased by removal of the endothelium. Endothelial destruction had no effect on the responses to either [Ala1,15]- or [Ala3,11]-ET-1. [Ala1,3,11,15]-ET-1 was not an agonist in vitro but was a partial agonist relative to ET-1 and [Ala1,15]- and [Ala3,11]-ET-1 in vivo. Also, the responses to [Ala1,15]-ET-1 in the blood-perfused preparation were best described by a two-site model. These results suggest that there may be two types of receptor for these peptides. In vivo, 5 mg/kg of indomethacin potentiated the maximum response to ET-1, suggesting that its actions may be opposed by vasodilator cyclo-oxygenase products.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473309     DOI: 10.1097/00005344-198900135-00055

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists.

Authors:  T D Warner
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

2.  Activities of endothelin-1 in the vascular network of the rabbit ear: a microangiographic study.

Authors:  M D Randall; D H Edwards; T M Griffith
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

3.  Binding of [125I]-endothelin-1 to rat cerebellar homogenates and its interactions with some analogues.

Authors:  C R Hiley; C R Jones; J T Pelton; R C Miller
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

4.  Effects of moderate hypoxia, hypercapnia and acidosis on haemodynamic changes induced by endothelin-1 in the pithed rat.

Authors:  M R MacLean; M D Randall; C R Hiley
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

5.  Circulating endothelin in children with congenital heart disease.

Authors:  I Adatia; S G Haworth
Journal:  Br Heart J       Date:  1993-03

6.  Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat.

Authors:  S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

7.  Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

8.  Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat.

Authors:  M D Randall; S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

9.  Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett; A P Davenport; L Edvinsson
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; R M Edwards; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.